1.Date of the shareholders’ meeting resolution:2023/06/16
2.Name and title of the managerial officer with permission to engage in competitive conduct:
Director Frank Chen, Representative of OBI Pharma, Inc.
Director Chung Yao Yin, Representative of RuentexSin, inc.
Director Yun Yen, Representative of OBI Pharma, Inc.
Director Jo Ma, Representative of OBI Pharma, Inc.
Director Hsing-Ming Chen, Representative of OBI Pharma, Inc.
3.Items of competitive conduct in which the officer is permitted to engage: Scope of business similar to that of Obigen.
4.Period of permission to engage in the competitive conduct: Duration of serving as a director of Obigen.
5.Circumstances of the resolution (please describe the results of voting in accordance with Article 209 of the Company Act):The resolution was adopted by a large majority of two thirds of
the shareholders of whom have voting rights and were present at the General Shareholders’ Meeting.
6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the directors (if it is not the operator of a mainland China enterprise, please enter “N/A” below): N/A
7.Company name of the mainland China enterprise and the officer’s position in the enterprise: N/A
8.Address of the mainland China enterprise: N/A
9.Operations of the mainland China enterprise: N/A
10.Impact on the company’s finance and business: N/A
11.If the directors have invested in the mainland China enterprise, the monetary amount of the investment and their shareholding ratio: N/A
12.Any other matters that need to be specified: None